F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi
Anglo-Austrian biotech F2G has raised $60.8 million in venture financing to help it bring a drug for life-threatening fungal infections through late-stage development and onto
The US drugs regulator has tagged F2G’s olorofim as a potential Breakthrough Therapy for life-threatening fungal infections, pledging to expedite development of the mid-stage candidate.
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.